A PHASE I STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES OF ORALLY ADMINISTERED APG-2575 IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Ascentage Pharma Group
Start Date
October 25, 2019
End Date
October 31, 2024
Administered By
Duke Cancer Institute
Awarded By
Ascentage Pharma Group
Start Date
October 25, 2019
End Date
October 31, 2024